Immunotherapy for treatment of periocular sarcoids in the horse

Sarcoids are the most common tumor diagnosed in horses and can be refractory to treatment despite multiple therapies to choose from. Some of these options include surgery, radiation, chemotherapy, cryotherapy, and immunotherapy each with varying degrees of success. Periocular sarcoids present a significant challenge given their proximity to the eyelids and globe. Several of the treatments currently used for sarcoids in other areas of the body, such as electrochemotherapy, induce significant inflammation and subsequent alteration in tissue function. Radiation is not widely available and can damage ocular structures and chemotherapy presents a human health risk.

Due to the limited treatment options for periocular sarcoids, an effective and safe alternative is needed to improve treatment of these tumors. Immunotherapy has shown promise in this area. While there has been some success using bovine papilloma virus (BPV) antigen to stimulate an immune response, the efficacy is approximately 50% for complete regression. A broad immune stimulant consisting of a liposome-toll like receptor complex (LTC) has the potential to be a safe and effective treatment for periocular sarcoids while maintaining normal function of the eyelids and globe.

Incentives

The immunotherapy is given at no cost. The only cost incurred is for the appointment and minor supplies.